by | Apr 24, 2024 | Publications
Photodermatol Photoimmunol Photomed. 2024 May;40(3):e12965. doi: 10.1111/phpp.12965. NO ABSTRACT PMID:38654582 | DOI:10.1111/phpp.12965
by | Apr 24, 2024 | Publications
Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print. ABSTRACT OBJECTIVES: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of...
by | Apr 24, 2024 | Publications
Cancer Epidemiol Biomarkers Prev. 2024 Apr 24. doi: 10.1158/1055-9965.EPI-23-1598. Online ahead of print. ABSTRACT BACKGROUND: Certain hazardous air pollutants (HAPs) are known or suspected to pose immunological or cancer risk to humans, but evidence is limited from...
by | Apr 24, 2024 | Publications
Front Oncol. 2024 Apr 9;14:1370854. doi: 10.3389/fonc.2024.1370854. eCollection 2024. ABSTRACT Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment...
by | Apr 17, 2024 | Publications
Clin Chem Lab Med. 2024 Apr 18. doi: 10.1515/cclm-2024-0416. Online ahead of print. ABSTRACT OBJECTIVES: This study evaluates the HYDRASHIFT assay’s effectiveness in mitigating daratumumab interference on serum protein tests during multiple myeloma (MM)...
by | Apr 17, 2024 | Publications
Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05733-9. Online ahead of print. ABSTRACT Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed patients and varying frequency...